These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6299621)

  • 1. Opiates control ACTH through a noradrenergic mechanism.
    Grossman A; Besser GM
    Clin Endocrinol (Oxf); 1982 Sep; 17(3):287-90. PubMed ID: 6299621
    [No Abstract]   [Full Text] [Related]  

  • 2. Adrenergic influence on iris stromal pigmentation: evidence for alpha-adrenergic receptors.
    Odin L; O'Donnell FE
    Invest Ophthalmol Vis Sci; 1982 Oct; 23(4):528-30. PubMed ID: 6288613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of alpha-2-adrenoceptors in the control of ACTH secretion; interaction with the opioid system.
    al-Damluji S; Bouloux P; White A; Besser M
    Neuroendocrinology; 1990 Jan; 51(1):76-81. PubMed ID: 1968233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone increases ACTH and cortisol levels in man.
    Volavka J; Cho D; Mallya A; Bauman J
    N Engl J Med; 1979 May; 300(18):1056-7. PubMed ID: 219337
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of naloxone on adrenocorticotrophin (ACTH) and cortisol in obese subjects.
    Satta MA; Maussier ML; De Rosa G; Valenza V; Testa A; Saletnich I; Napolitano G; Monaco F
    Horm Metab Res; 1992 Jan; 24(1):44-5. PubMed ID: 1319389
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of naloxone on ATCH and beta-endorphin in patients with Cushing's disease.
    Baranowska B; Dorobek W; Misiorowski W; Jeske W; Abdel-Fattah MH
    Acta Endocrinol (Copenh); 1985 Oct; 110(2):170-5. PubMed ID: 2998130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naloxone potentiation of novelty-induced hypoalgesia: characterization of the alpha-noradrenergic receptor subtype.
    Rochford J; Dawes P; Stewart J
    Pharmacol Biochem Behav; 1993 Feb; 44(2):381-6. PubMed ID: 8383341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of pharmacological stimulation and blockade of alpha-adrenergic receptors on adrenocorticotropic hormone and cortisol in the blood of people of various age].
    Shatylo VB; Fedirko MI
    Fiziol Zh (1994); 1994; 40(2):15-9. PubMed ID: 7758598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opiate receptor blockade and diurnal pituitary and adrenal hormone levels.
    Leslie RD; Prescott RW; Kendall-Taylor P; Cook D; Weightman D; Ratcliffe J; Ingram MC
    Horm Metab Res; 1985 Feb; 17(2):86-9. PubMed ID: 2985486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre- and postsynaptic alpha-adrenergic effects of clonidine in major depressive disorder.
    Lesch KP; Laux G; Schulte HM; Erb A; Pfüller H; Beckmann H
    Pharmacopsychiatry; 1988 Nov; 21(6):430-1. PubMed ID: 2854278
    [No Abstract]   [Full Text] [Related]  

  • 11. Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man.
    Delitala G; Trainer PJ; Oliva O; Fanciulli G; Grossman AB
    J Endocrinol; 1994 Apr; 141(1):163-8. PubMed ID: 8031419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-receptor subsensitivity of isolated atria from rats following physical training or repeated ACTH-injections.
    Siltovuori A; Tirri R; Harri MN
    Acta Physiol Scand; 1977 Apr; 99(4):457-61. PubMed ID: 193357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH, follicle-stimulating hormone, prolactin, and beta-endorphin secretion.
    Baranowska B; Rozbicka G; Jeske W; Abdel-Fattah MH
    J Clin Endocrinol Metab; 1984 Sep; 59(3):412-6. PubMed ID: 6086696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of desipramine on basal and naloxone-stimulated cortisol secretion in humans: interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion.
    Torpy DJ; Grice JE; Hockings GI; Crosbie GV; Walters MM; Jackson RV
    J Clin Endocrinol Metab; 1995 Mar; 80(3):802-6. PubMed ID: 7883833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of naloxone on oxytocin-induced cortisol decrease in normal men.
    Coiro V; Chiodera P; Rossi G; Volpi R; Salvi M; Camellini L; Roti E
    Acta Endocrinol (Copenh); 1985 Feb; 108(2):261-5. PubMed ID: 2982243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low-dose naloxone infusion on plasma ACTH and LH in patients with Cushing's and Addison's diseases.
    Moreira AC; Foss MC; Iazigi N; Verissimo JM
    Horm Metab Res; 1988 Apr; 20(4):230-4. PubMed ID: 2840381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of alpha-adrenergic responsiveness to clonidine challenge and noradrenergic metabolism in the affective disorders and their treatment.
    Siever LJ; Uhde TW; Silberman EK; Lake CR; Jimerson DC; Risch SC; Kalin NH; Murphy DL
    Psychopharmacol Bull; 1982 Oct; 18(4):118-9. PubMed ID: 6296907
    [No Abstract]   [Full Text] [Related]  

  • 18. Oxytocin reduces exercise-induced ACTH and cortisol rise in man.
    Coiro V; Passeri M; Davoli C; Bacchi-Modena A; Bianconi L; Volpi R; Chiodera P
    Acta Endocrinol (Copenh); 1988 Nov; 119(3):405-12. PubMed ID: 2847472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulatory effect of naloxone on plasma cortisol in human: Possible direct stimulatory action at the adrenal cortex.
    Coiro V; Volpi R; Stella A; Venturi N; Chiodera P
    Regul Pept; 2011 Jan; 166(1-3):1-2. PubMed ID: 20728478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet alpha 2-adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment.
    García-Sevilla JA; Zis AP; Hollingsworth PJ; Greden JF; Smith CB
    Arch Gen Psychiatry; 1981 Dec; 38(12):1327-33. PubMed ID: 6274267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.